The European Medicines Agency is this week set to decide whether to recommend pan-EU marketing approval for 15 new drugs, including Xevudy (sotrovimab),Vir Biotechnology/GlaxoSmithKline’s COVID-19 treatment, and linzagolix, from ObsEva, for managing heavy menstrual bleeding associated with uterine fibroids.
Xevudy, which is approved in a number of countries around the world, is intended for the treatment of adults and...








